ADVANCING THE USE & GENERATION OF REAL WORLD EVIDENCE ACROSS DRUG LIFE CYCLE
Real World Evidence is at the root of an ongoing and critical transformation in medical care. By incorporating data from the real-world into their development programs, drug developers are more than ever now able to drive more patient-facing outcomes, by supporting it with effective evidence-based decision-making across the product life cycle.
Our mission for the 7th IMPACCT: Real World Evidence meeting is simple: Build a collaborative forum that unites forward thinking industry leaders and innovators active in the RWE space for a comprehensive and open discussion on how to support and advance the generation and utilization of RWE across drug life cycle, from clinical R&D to commercialization.
Just some of our expert speakers already confirmed include:
- Tony Hebden, VP, HEOR, AbbVie
- Javier Jimenez, VP & Global Head of RWE & Clinical Outcomes, Sanofi
- Danny Wiederkehr, Senior Director, Global HEOR Team, Pfizer
- Sebastian Schneeweiss, Professor of Medicine & Epidemiology, Harvard Medical School
- Melvin Olson, Global Head of RWD Strategy & Innovation, Novartis
- Cathy Critchlow, VP, Center for Observational Research, Amgen
- Keith Friend, Global Medical Director, Cardiovascular, Bristol-Myers Squibb
- Mandeep Kaur, VP & Head of North America Medical Affairs for Immunology, Sanofi
- John Graham, SVP, Medical Engagement & Value Evidence & Outcomes, GlaxoSmithKline
- Michael Lees, Head of Value, Evidence & Portfolio, Takeda
Join the discussion alongside 80+ highly focused peers and leaders for exclusive insights that will inspire you to successfully drive patient-facing innovation across the product life-cycle.
Click here to see the full program and speaker line-up: http://bit.ly/2RVqYJX
We hope you can join us. Pharma Journalist readers receive an exclusive 10% discount to attend the forum. Simply quote VIP Code PJPR10 at checkout to receive your discount.
We hope you’ll be able to join us.
The IMPACCT: Real World Evidence Team